Correction: Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year Data from the COAST program (Journal of Rheumatology (2023) DOI: 10.3899/jrheum.221022)

Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung, Désirée van der Heijde

Research output: Contribution to journalComment/debatepeer-review

Abstract

Figure 1 was incomplete. The corrected Figure 1 appears here. This version contains all the reasons for discontinuation, including “lack of efficacy.” The “completed study” number and percentage were also corrected, and 2 footnotes were added for clarity:“a Seven hundred seventy-three of 932 (82.9%) patients reconsented and entered COAST-Y after completing their original study.b Six hundred thirty-one of 932 (67.7%) patients completed 156 weeks of treatment and 12 weeks of follow-up.” This correction applies only to the March 1 2023 First Release. The correct text appears in the print and online issues (Figure Presented).

Original languageEnglish (US)
Pages (from-to)718
Number of pages1
JournalJournal of Rheumatology
Volume50
Issue number5
DOIs
StatePublished - May 1 2023

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Correction: Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year Data from the COAST program (Journal of Rheumatology (2023) DOI: 10.3899/jrheum.221022)'. Together they form a unique fingerprint.

Cite this